NCT02266940已完成1 期
A Phase 1, Open Label, Randomised, Single Dose, Three Way Crossover Study to Explore the Relative Bioavailability of DS 1971a Given as a 200 mg Tablet Formulation and a 200 mg Oral Suspension, and to Explore the Effects of Administration With a High Fat Meal on the Relative Bioavailability of the Tablet Formulation
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Pharmacokinetics profile of DS-1971a
研究概览
简要总结
This is an open label, randomised, 3 treatment, 3 period crossover study. This study is designed to assess the relative bioavailability of DS 1971a from a tablet formulation and a reconstituted oral suspension and the effect of a high fat meal on the relative bioavailability of DS 1971a from the tablet formulation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female subjects aged 18 to 65 years, inclusive
- •Subjects must be in good general health as determined by medical history, physical examination and screening investigations, and be taking no regular medication
- •A body mass index (BMI) in the range 18 to 30 kg/m^2, inclusive, and weighing between 50 and 100 kg. BMI is calculated as weight [kg]/(height [m])^2
- •Female subjects must be of nonchildbearing potential as follows:
- •Must be postmenopausal (the last menstrual period was at least 12 months before Screening, and a follicle stimulating hormone [FSH] test at Screening confirms postmenopausal status); or Must be surgically sterile having undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy and/or bilateral tubal ligation
- •Willing and able to consume a standard Food and Drug Administration (FDA) high fat meal
- •Willing to comply with all study restrictions, including the use of contraception, concomitant medication, and dietary and lifestyle restrictions
- •Sufficient intelligence to understand the nature of the study and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study
- •Have given written consent to participate after reading the information and consent form, and after having the opportunity to discuss the study with the Investigator or his/her delegate
- •Have given written consent to have his/her data entered into The Over-volunteering Prevention System (TOPS)
排除标准
- •Clinically relevant abnormal history, physical findings, ECG findings, or laboratory values that could interfere with the objectives of the study or the safety of the subject
- •Presence of or history of acute or chronic illness, including (but not limited to) liver or kidney disease, hypertension, seizures, or any known impairment of endocrine, or other specific body-organ dysfunction
- •Presence or history of severe adverse reaction to any medicine
- •Presence or history of malignant disease
- •Acute or chronic infectious disease, including human immunodeficiency virus (HIV), hepatitis B virus (HBV) or C virus (HCV) infection
- •Surgery (eg, stomach bypass) or medical condition that might affect absorption of medicines
- •Significant illness within 4 weeks before the dose of study medication
- •Participation in another clinical study of a new chemical entity or a prescription medicine within the previous 3 months, or unwilling to abstain from participating in other clinical studies during the study and for 3 months after receipt of their final dose of study medication
- •Participation in another clinical study with DS-1971a
- •Blood pressure (BP) and heart rate in semi supine position at the screening examination outside the ranges 90-140 mmHg systolic, 40-90 mmHg diastolic; heart rate 40-100 beats/min. Subjects with Stage 1 hypertension (systolic 140 160 mmHg; diastolic 90 100 mmHg) may be enrolled provided they do not have evidence of end organ damage, diabetes or a 10 year cardiovascular risk >20%
- •Estimated glomerular filtration rate (eGFR) <80 mL/min/1.73m^2 or an absolute creatinine value above the upper limit of normal (ULN). eGFR will be estimated at Screening using the modification of diet in renal disease (MDRD) equation
- •Abnormal ECG waveform morphology at Screening that would preclude accurate measurement of the QT interval duration
- •Corrected QT interval (Fridericia's formula) (QTcF) interval duration >430 msec for men or >450 msec for women, obtained as an average from the measurements on duplicate screening ECGs
- •Use of any prescription medicine or over-the-counter (OTC) medications, herbal remedies (such as St John's Wort), or food known to be strong inhibitors or strong inducers of cytochrome (CYP) enzymes (also known as CYP450 enzymes) during the 30 days before the dose of study medication; use of any other prescription or OTC medicine, including dietary supplements or herbal remedies, during the 7 days before the first dose of study medication
- •Consumption of certain foods or beverages before the dose and throughout the study period
- •Loss of more than 400 mL blood during the 3 months before the study, eg, as a blood donor
- •Abuse of drugs or alcohol during the 2 years before the first dose of study medication, or intake of more than 21 units of alcohol weekly (for men) or 14 units of alcohol weekly (for women)
- •Use of tobacco products or nicotine containing products during the 3 months before the dose of trial medication
- •Likely possibility that the volunteer will not cooperate with the requirements of the protocol
- •Objection by General Practitioner (GP) to volunteer entering the study
研究组 & 干预措施
200mg DS-1971a oral suspension fasted
Experimental
200 mg DS 1971a given as oral suspension in fasted condition
干预措施: DS-1971a suspension (Drug)
200 mg DS-1971a tablet fasted
Experimental
single 200 mg DS 1971a oral tablet in fasted condition
干预措施: DS-1971a tablet (Drug)
200 mg DS-1971a tablet fed
Experimental
single 200 mg DS 1971a oral tablet given in fed condition
干预措施: DS-1971a tablet (Drug)
结局指标
主要结局
Pharmacokinetics profile of DS-1971a
时间窗: 3 days from dose administration
Plasma concentration time data will be analysed using non compartmental methods. The following PK parameters will be estimated: Cmax, Tmax and AUClast. If data permit, AUC0-inf, CL/F, Vd/F and T½ will be estimated.
次要结局
- changes in clinical laboratory profile(administration of first dose to 10 weeks)
- changes in physical exam profile(administration of first dose to 10 weeks)
- number and severity of adverse events as a measure of safety and tolerability(administration of first dose to 10 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy ParticipantsHealthy VolunteersNCT06397508Agomab Spain S.L.25
已完成
1 期
Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy VolunteersChronic Kidney DiseaseNCT04734275AstraZeneca16
已完成
1 期
A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy SubjectsHealthy SubjectsNCT05150626CSPC ZhongQi Pharmaceutical Technology Co., Ltd.21
已完成
1 期
Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female SubjectsHealthy VolunteersPharmacologic ActionNCT02039180AstraZeneca1
Unknown
1 期
Pharmacometabolomics of Andrographis Paniculata And Metformin In Healthy Volunteers Under Fasting ConditionPharmacokineticsMolecular Mechanisms of Pharmacological ActionNCT04161404University of Malaya18